Hemophilia Spin-Off Hemophilia Spin-Off (Details Textual) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Feb. 01, 2017
Assets and Liabilities Distributed to Bioverativ [Line Items]
Product Revenues	$ 3,526.3	$ 3,439.0	$ 3,356.5	$ 3,131.1	$ 3,307.0	$ 3,077.8	$ 3,078.4	$ 2,810.7	$ 13,452.9	$ 12,273.9	$ 11,448.8
Cost of Sales									1,816.3	1,630.0	1,478.7
Bioverativ
Assets and Liabilities Distributed to Bioverativ [Line Items]
Cash												$ 302.7
Cost of Sales									180.4	15.1
Other revenue
Assets and Liabilities Distributed to Bioverativ [Line Items]
Product Revenues	165.7	$ 147.2	$ 108.6	$ 164.4	$ 179.6	$ 48.8	$ 41.6	$ 90.0	585.9	360.0	316.4
Other revenue | Bioverativ
Assets and Liabilities Distributed to Bioverativ [Line Items]
Product Revenues									206.7	64.8
Hemophilia Products
Assets and Liabilities Distributed to Bioverativ [Line Items]
Product Revenues									0.0	$ 74.4	$ 846.9
Bioverativ
Assets and Liabilities Distributed to Bioverativ [Line Items]
Inventory expected to be sold to Bioverativ	$ 180.0								$ 180.0